<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00911508</url>
  </required_header>
  <id_info>
    <org_study_id>09-004616</org_study_id>
    <secondary_id>U01HL089709</secondary_id>
    <nct_id>NCT00911508</nct_id>
  </id_info>
  <brief_title>Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial</brief_title>
  <acronym>CABANA</acronym>
  <official_title>Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Abbott Medical Devices</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Biosense Webster, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The (Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial)
      CABANA Trial has the overall goal of establishing the appropriate roles for medical and
      ablative intervention for atrial fibrillation (AF). The CABANA Trial is designed to test the
      hypothesis that the treatment strategy of left atrial catheter ablation for the purpose of
      eliminating atrial fibrillation (AF) will be superior to current state-of-the-art therapy
      with either rate control or rhythm control drugs for decreasing the incidence of the
      composite endpoint of total mortality, disabling stroke, serious bleeding, or cardiac arrest
      in patients with untreated or incompletely treated AF.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The need for this trial arises out of 1) the rapidly increasing number of pts &gt; 60 years of
      age with AF accompanied by symptoms and morbidity, 2) the failure of anti-arrhythmic drug
      therapy to maintain sinus rhythm and reduce mortality, 3) the rapidly increasing application
      of radio-frequency catheter ablation without appropriate evidence-based validation, and 4)
      the expanding impact of AF on health care costs.

      This study will randomize up to 2200 patients to a strategy of catheter ablation versus
      pharmacologic therapy with rate or rhythm control drugs. Each pt will have 1) characteristics
      similar to AFFIRM pts (≥65 yo or &lt;65 with &gt;1 risk factor for stroke, 2) Documented AF
      warranting treatment, and 3) Eligibility for both catheter ablation and ≥2 anti-arrhythmic or
      ≥2 rate control drugs. Pts will be followed every 6 months for an average of approximately 5
      years and will undergo repeat trans-telephonic monitor, Holter monitor, and CT/MR studies to
      assess the impact of treatment.

      The CABANA trial will disclose the role of medical and non-pharmacologic therapies for AF,
      establish the cost and impact of therapy on quality of life and will help determine if AF is
      a modifiable risk factor for increased mortality.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 13, 2009</start_date>
  <completion_date type="Actual">December 31, 2017</completion_date>
  <primary_completion_date type="Actual">December 31, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Composite of Total Mortality, Disabling Stroke, Serious Bleeding, or Cardiac Arrest in Patients Warranting Therapy for AF.</measure>
    <time_frame>From date of enrollment until time-to-first event over a median follow-up of 48.5 months.</time_frame>
    <description>All events for each component of the primary endpoint were reviewed and adjudicated in a blinded fashion by an independent clinical events committee using prospectively determined event definitions. Death was defined as all-cause mortality, disabling stroke (including intracranial bleeding) as an irreversible physical limitation defined by a Rankin Stroke Scale ≥2, and serious bleeding as bleeding accompanied by hemodynamic compromise that required surgical intervention or a transfusion of ≥3 units of blood.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All-cause Mortality</measure>
    <time_frame>From date of enrollment until date of death over a median follow-up of 48.5 months.</time_frame>
    <description>All deaths were reviewed and adjudicated by the Clinical Events Committee</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Mortality or Cardiovascular (CV) Hospitalization</measure>
    <time_frame>From date of enrollment until time-to-first event of death or CV hospitalization over a median follow-up of 48.5 months.</time_frame>
    <description>Hospitalization was characterized by the site principal investigator (PI) and reported as part of the hospitalization case report form.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Mortality, Disabling Stroke, or CV Hospitalization (for Heart Failure or Acute Ischemic Events)</measure>
    <time_frame>From date of enrollment until time-to-first event of death, stroke, or CV hospitalization (for heart failure or acute ischemic event) over a median follow-up of 48.5 months.</time_frame>
    <description>Disabling stroke (including intracranial bleeding) was defined as an irreversible physical limitation defined by a Rankin Stroke Scale ≥2 and the reason for hospitalization was characterized by the site PI and reported as part of the hospitalization case report form.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Cardiovascular Death</measure>
    <time_frame>From date of enrollment until date of a cardiovascular death over a median follow-up of 48.5 months.</time_frame>
    <description>Cardiovascular death as determined by the Clinical Events Committee based on the available data provided by the Principal Investigator</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Cardiovascular Death or Disabling Stroke</measure>
    <time_frame>From date of enrollment until time-to-first event of a cardiovascular death or disabling stroke over a median follow-up of 48.5 months.</time_frame>
    <description>Disabling stroke (including intracranial bleeding) was defined as an irreversible physical limitation defined by a Rankin Stroke Scale ≥2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With an Arrhythmic Death or Cardiac Arrest</measure>
    <time_frame>From date of enrollment until time-to-first event for an arrhythmic death or cardiac arrest over a median follow-up of 48.5 months.</time_frame>
    <description>All deaths and cardiac arrest events were adjudicated by the Clinical Events Committee</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Heart Failure Death</measure>
    <time_frame>From date of enrollment until date of heart failure death over a median follow-up of 48.5 months.</time_frame>
    <description>All deaths were categorized and adjudicated by the Clinical Events Committee</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Free From Recurrent Atrial Fibrillation (AF) Following the 90 Day Blanking Period</measure>
    <time_frame>From date of therapy initiation until date of first AF recurrence following a 90 day wait (blanking) period over a median follow-up of 48.5 months.</time_frame>
    <description>Data from patients using the study provided ECG event recording system were analyzed. A 30-second episode of AF in either group, confirmed through blinded review by an ECG Core Lab Committee was used for defining the endpoint of recurrent AF.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Cardiovascular Hospitalization</measure>
    <time_frame>From date of enrollment until date of cardiovascular hospitalization over a median follow-up of 48.5 months.</time_frame>
    <description>The reason for hospitalization was characterized by the site PI and reported as part of the hospitalization case report form.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Quality of Life Measures - AFEQT</measure>
    <time_frame>Baseline ,12 month, 5 years</time_frame>
    <description>Atrial Fibrillation Effect on Quality of Life (AFEQT) Overall Score (Scale: 0 = complete disability, 100 = no disability). The AFEQT is a 21-item AF-specific, health-related QOL questionnaire designed to assess the effect of atrial fibrillation on patient quality of life. The AFEQT has an Overall Score (calculated from 18 of the questions) and subscale scores in three domains: symptoms, daily activities, and treatment concern. Overall and subscale scores range from 0 (corresponds to complete disability) to 100 (no AF-related disability).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Quality of Life Measures - MAFSI Frequency Score</measure>
    <time_frame>Baseline, 12 Month, 5 Year</time_frame>
    <description>The Mayo AF-Specific Symptom Inventory (MAFSI) is a questionnaire comprised of a 10-item AF symptom checklist that asked about both the frequency and severity of each symptom. MAFSI frequency of symptoms over the past month was recorded as 0 (never), 1 (rarely), 2 (sometimes), 3 (often), and 4 (always) for each of the 10 items listed in the questionnaire. The 10 item responses were summed for a total Frequency Score that ranged from 0 (no AF symptoms) to 40 (worst score).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Quality of Life Measures - MAFSI Severity Score</measure>
    <time_frame>Baseline, 12 Month, 5 Year</time_frame>
    <description>The Mayo AF-Specific Symptom Inventory (MAFSI) is a questionnaire comprised of a 10-item AF symptom checklist that asked about both the frequency and severity of each symptom. MAFSI severity scores over the past month were recorded as 1 (mild), 2 (moderate), and 3 (extreme) for each of the 10 items listed in the questionnaire. The 10 items items were then summed for the total Severity Score that ranged from 0 (no AF symptoms) to 30 (most severe AF symptoms).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events/Complications</measure>
    <time_frame>From treatment start date to date of event over a median follow-up of 48.5 months.</time_frame>
    <description>Comparing individual non-endpoint adverse events between ablative and drug therapy is difficult due to the substantial difference in the types of adverse events expected.
Ablation-related events were counted among all patients that were randomized to and received an ablation.
Drug-related events were counted among all patients that were randomized to and received drug therapy.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2204</enrollment>
  <condition>Atrial Fibrillation</condition>
  <condition>Arrhythmia</condition>
  <arm_group>
    <arm_group_label>Left Atrial Ablation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pulmonary vein isolation using a circumferential ablative approach in the left atrium. Ablation may be performed using circular mapping catheter-guided ablation, antral isolation using a circular guided approach, or wide area circumferential ablation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rate or Rhythm Control Therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Current state-of-the-art drug therapy for atrial fibrillation (rate control or rhythm control). Treating physicians will be encouraged to follow the American College of Cardiology / American Heart Association / European Society of Cardiology Atrial Fibrillation Guidelines with regard to drug therapy for atrial fibrillation. The specific choice of rate control versus rhythm control drug therapy and the specific drugs to be used will ultimately be left to the discretion of the treating physician.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Left atrial ablation</intervention_name>
    <description>St. Jude: Livewire TC™ , Therapy™ Dual / Thermocouple, Safire,Therapy Cool Path
Biosense Webster: NAVI-STAR, NAVI-STAR/NAVI-STAR DS, Celsius Braided/Long Tip, NAVI-STAR™ and Celsius™ ThermoCool, NAVI-STAR® RMT, Celsius® RMT, ThermoCool® SF
Medtronic CryoCath LP: Freezor®/Freezor MAX®, Artic Front®, Cardiac Ablation System
Bard: Stinger
Boston Scientific: Blazer II RF/XP, Blazer RPM, Chilli II Cooled, SteeroCath</description>
    <arm_group_label>Left Atrial Ablation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rate or Rhythm Control Therapy</intervention_name>
    <description>Rate control: Metoprolol 50-100mg, Atenolol 50-100mg, Propranolol 40-80mg, Acebutolol 200-300mg, Carvedilol 6.25-25mg, Diltiazem 180-240mg, Verapamil 180-240mg, Digoxin 0.125-0.25mg
Rhythm control: Propafenone 450-625mg, Flecainide 200-300mg, Sotalol 240-320mg, Dofetilide 500-1000mcg, Amiodarone 200-400mg, Quinidine 600-900mg, Dronedarone 800mg</description>
    <arm_group_label>Rate or Rhythm Control Therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Over the preceding 6 months have:

               1. ≥2 paroxysmal (electrocardiographic documentation of at least 1) atrial
                  fibrillation (AF) episodes lasting ≥1 hour in duration: (that terminate
                  spontaneously within 7 days or cardioversion is performed within 48h of AF
                  onset): or

               2. electrocardiographic documentation of 1 persistent AF episode: (sustained for ≥7
                  days or cardioversion is performed more than 48h after AF onset): or

               3. electrocardiographic documentation of 1 longstanding persistent AF episode:
                  (continuous AF of duration &gt;1 year).

          -  Warrant active therapy (within the past 3 months) beyond simple ongoing observation

          -  Be eligible for catheter ablation and ≥2 sequential rhythm control and/or ≥2 rate
             control drugs.

          -  Be ≥65 yrs of age, or &lt;65 yrs with one or more of the following risk factors for
             stroke: Hypertension (treated and/or defined as a blood pressure &gt;140/90 mmHg) [90],
             Diabetes (treated and/or defined as a fasting glucose ≥126 mg/dl) [91], Congestive
             heart failure (including systolic or diastolic heart failure), Prior stroke, transient
             ischemic attack or systemic emboli, Atherosclerotic vascular disease (previous
             myocardial infarction (MI), peripheral arterial disease or aortic plaque), left atrial
             (LA) size &gt;5.0 cm (or volume index ≥40 cc/m2), or ejection fraction (EF) ≤35.

          -  Have the capacity to understand and sign an informed consent form.

          -  Be ≥18 years of age.

               -  NOTE- Subjects &lt;65 yrs of age whose only risk factor is hypertension must have a
                  second risk factor or left ventricular (LV) hypertrophy to qualify.Patients
                  receiving new drug therapy initiated within the previous 3 months may continue
                  that therapy if randomized to the drug therapy arm. Patients may have documented
                  atrial flutter in addition to atrial fibrillation and remain eligible for
                  enrollment.

        Exclusion Criteria:

          -  Lone AF in the absence of risk factors for stroke in patients &lt;65 years of age

          -  Patients who in the opinion of the managing clinician should not yet receive any
             therapy for AF

          -  Patients who have failed &gt;2 membrane active anti-arrhythmic drugs at a therapeutic
             dose due to inefficacy or side effects (Table 5.2.2)

          -  An efficacy failure of full dose amiodarone treatment &gt;8 weeks duration at any time

          -  Reversible causes of AF including thyroid disorders, acute alcohol intoxication,
             recent major surgical procedures, or trauma

          -  Recent cardiac events including MI, percutaneous intervention (PCI), or valve or
             bypass surgery in the preceding 3 months

          -  Hypertrophic obstructive cardiomyopathy (outflow track)

          -  Class IV angina or Class IV congestive heart failure (CHF) (including past or planned
             heart transplantation)

          -  Other arrhythmias mandating anti-arrhythmic drug therapy (i.e. ventricular tachycardia
             (VT), ventricular fibrillation (VF))

          -  Heritable arrhythmias or increased risk for torsade de pointes with class I or III
             drugs

          -  Prior LA catheter ablation with the intention of treating AF

          -  Prior surgical interventions for AF such as the MAZE procedure

          -  Prior AV nodal ablation

          -  Patients with other arrhythmias requiring ablative therapy

          -  Contraindication to appropriate anti-coagulation therapy

          -  Renal failure requiring dialysis

          -  Medical conditions limiting expected survival to &lt;1 year

          -  Women of childbearing potential (unless post-menopausal or surgically sterile)

          -  Participation in any other clinical mortality trial (Participation in other
             non-mortality trials should be reviewed with the clinical trial management center)

          -  Unable to give informed consent

               -  NOTE- Prior ablation of the cavo-tricuspid isthmus alone is not an exclusion if
                  the patient develops subsequent recurrent AF. Planned atrial flutter ablation in
                  combination with the left atrial ablation is not an exclusion.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Douglas L. Packer, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kerry L. Lee, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke Clinical Research Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Daniel B. Mark, M.D., MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke Clinical Research Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rich A. Robb, Ph.D. Phy</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yves D. Rosenberg, M.D., MPH</last_name>
    <role>Study Chair</role>
    <affiliation>National Heart, Lung, and Blood Institute (NHLBI)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Arkansas Cardiology, PA</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Good Samaritan Hospital</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California Davis Medical Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California at San Francisco Medical Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University Medical Center</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Medical Center of Aurora</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Penrose Saint Francis Health Services</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80907</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hartford Hospital</name>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <zip>06115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>George Washington University Medical Faculty Associates</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami Hospital</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Hospital</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northside Hospital and Heart Institute</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33709</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tallahassee Memorial Hospital</name>
      <address>
        <city>Tallahassee</city>
        <state>Florida</state>
        <zip>32308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Heart Rhythm-University of South Florida College of Medicine</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgia Regents University</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgia Arrhythmia Consultants &amp; Research Institute</name>
      <address>
        <city>Macon</city>
        <state>Georgia</state>
        <zip>31201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alexian Brothers Medical Center</name>
      <address>
        <city>Barrington</city>
        <state>Illinois</state>
        <zip>60010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NorthShore University Health System</name>
      <address>
        <city>Evanston</city>
        <state>Illinois</state>
        <zip>60201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Loyola University Medical Center</name>
      <address>
        <city>Maywood</city>
        <state>Illinois</state>
        <zip>60153</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy Medical Center-Iowa Heart Center</name>
      <address>
        <city>West Des Moines</city>
        <state>Iowa</state>
        <zip>50226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brigham and Womens Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Joseph Mercy Hospital</name>
      <address>
        <city>Ypsilanti</city>
        <state>Michigan</state>
        <zip>48197</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minneapolis V.A. Medical Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55417</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Park Nicollet Methodist Hospital</name>
      <address>
        <city>Saint Louis Park</city>
        <state>Minnesota</state>
        <zip>55426</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jackson Heart Clinic</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint John's Mercy Heart Health Center</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Louis Heart and Vascular</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cooper University Hospital</name>
      <address>
        <city>Camden</city>
        <state>New Jersey</state>
        <zip>08103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Robert Wood Johnson University Hospital</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albany Associates in Cardiology</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York University Langone Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stony Brook University Hospital and Medical Center</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11794-8167</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Carolina at Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Sanger Clinic, PA</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest University Health Sciences</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44193</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oklahoma Heart Institute</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Saint Vincent Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Geisinger Wyoming Valley Medical Center</name>
      <address>
        <city>Danville</city>
        <state>Pennsylvania</state>
        <zip>17822-2160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Penn State University Cardiovascular Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Drexel University College of Medicine</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania Health System</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>V.A. Pittsburgh Healthcare System</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15240</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lankenau Hospital</name>
      <address>
        <city>Wynnewood</city>
        <state>Pennsylvania</state>
        <zip>19096</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Greenville Hospital System University Medical Center</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Health Care System</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Cardiac Arrhythmia</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor Heart and Vascular Hospital</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor All Saints Medical Center</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Science Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Heart Hospital Baylor Plano</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Texas Cardiovascular Consultants</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78299</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scott and White Memorial Hospital</name>
      <address>
        <city>Temple</city>
        <state>Texas</state>
        <zip>76508</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Intermountain Medical Center-LDS Hospital</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Virginia Health System</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Hospital Center - Arlington</name>
      <address>
        <city>Falls Church</city>
        <state>Virginia</state>
        <zip>22042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sentara Norfolk General Hospital</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University Medical Center</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Swedish Medical Center - Providence Campus</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiac Study Center</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Waukesha Memorial Hospital</name>
      <address>
        <city>Waukesha</city>
        <state>Wisconsin</state>
        <zip>53188</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Adelaide Hospital</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Melbourne Hospital</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Calgary</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 2T9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hamilton Health Sciences</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8L 2X2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Western Ontario - London Health Sciences Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5A5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southlake Regional Health Centre</name>
      <address>
        <city>Newmarket</city>
        <state>Ontario</state>
        <zip>L3Y 8C3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guangdong Provincial People's Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>First Affiliated Hospital of Nanjing Medical University</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210029</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>First Affiliated Hospital of Dalian Medical University</name>
      <address>
        <city>Dalian</city>
        <state>Liaoning</state>
        <zip>116011</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beijing Anzhen Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100029</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fuwai Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100037</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Na Homolce Hospital</name>
      <address>
        <city>Prague 5</city>
        <state>Hlavni Mesto Praha</state>
        <zip>150 30</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Anne's University Hospital, ICRC</name>
      <address>
        <city>Brno</city>
        <zip>65691</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charles University</name>
      <address>
        <city>Prague 2</city>
        <zip>12808</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinic of Cardiology IKEM Medical Institute</name>
      <address>
        <city>Prague 4</city>
        <zip>14021</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Mannheim</name>
      <address>
        <city>Mannheim</city>
        <state>Baden-Wurttemberg</state>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Coburg</name>
      <address>
        <city>Coburg</city>
        <state>Bayern</state>
        <zip>96450</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitares Herrzentrum Hamburg</name>
      <address>
        <city>Hamburg</city>
        <state>Freie-Hansestadt Hamburg</state>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herz-und Diabeteszentrum NRW</name>
      <address>
        <city>Bad Oeynhausen</city>
        <state>Nordrhein-Westfalen</state>
        <zip>D-32545</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Technische Universitat Dresden</name>
      <address>
        <city>Dresden</city>
        <state>Saxony</state>
        <zip>D-01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kerckhoff Klinik</name>
      <address>
        <city>Bad Nauheim</city>
        <zip>D-61231</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxisklinik Herz and GefaBe</name>
      <address>
        <city>Dresden</city>
        <zip>01324</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCB - Cardioaniologisches Centrum Bethanien</name>
      <address>
        <city>Frankfurt</city>
        <zip>60431</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georg-August-University</name>
      <address>
        <city>Gottingen</city>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asklepios Klinik St. Georg</name>
      <address>
        <city>Hamburg</city>
        <zip>20099</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asklepios Klinik Barmbek</name>
      <address>
        <city>Hamburg</city>
        <zip>22291</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Vincentius-Kliniken</name>
      <address>
        <city>Karlsruhe</city>
        <zip>76137</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herzzentrum Leipzig</name>
      <address>
        <city>Leipzig</city>
        <zip>04289</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitat Rostock</name>
      <address>
        <city>Rostock</city>
        <zip>D-18057</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico San Donato Center of Clinical Arrhythmia and Electrophysiology</name>
      <address>
        <city>San Donato Milanese</city>
        <state>Lombardia</state>
        <zip>20097</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Multimedical Cardiology and Arrhythmia Centre</name>
      <address>
        <city>Milan</city>
        <zip>20099</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale di Circolo e Fondazione Macchi</name>
      <address>
        <city>Varese</city>
        <zip>21100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Korea University Anam Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yonsei University Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Institute of Circulation of Pathology</name>
      <address>
        <city>Novosibirsk</city>
        <state>Novosibirskaya Oblast</state>
        <zip>630055</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Hospital # 83 under the Federal Medical and Biological Agency</name>
      <address>
        <city>Moscow</city>
        <zip>115682</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bakoulev Scientific Center for Cardiovascular Surgery</name>
      <address>
        <city>Moscow</city>
        <zip>121552</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scientific Research Institute of Cardiology of Ministry of Health of Russian Foundation</name>
      <address>
        <city>Tomsk</city>
        <zip>634012</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Golden Jubilee Hospital</name>
      <address>
        <city>Glasgow</city>
        <zip>G81 4HX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Bartholomew's Hospital</name>
      <address>
        <city>London</city>
        <zip>EC1A 7BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint George's Hospital Medical School</name>
      <address>
        <city>London</city>
        <zip>SW17 0QT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Mary's Hospital</name>
      <address>
        <city>London</city>
        <zip>W2 1NY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>China</country>
    <country>Czechia</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Russian Federation</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Brazil</country>
    <country>Czech Republic</country>
    <country>France</country>
    <country>Taiwan</country>
  </removed_countries>
  <link>
    <url>http://clinicaltrials.mayo.edu</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>May 28, 2009</study_first_submitted>
  <study_first_submitted_qc>May 29, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 2, 2009</study_first_posted>
  <results_first_submitted>December 26, 2018</results_first_submitted>
  <results_first_submitted_qc>August 22, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">August 26, 2019</results_first_posted>
  <last_update_submitted>August 22, 2019</last_update_submitted>
  <last_update_submitted_qc>August 22, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Douglas L. Packer</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Atrial Fibrillation</keyword>
  <keyword>Left Atrial Ablation</keyword>
  <keyword>Pulmonary Vein Isolation</keyword>
  <keyword>Catheter Ablation</keyword>
  <keyword>Antiarrhythmic Drug Therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>November 22, 2013</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/08/NCT00911508/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 26, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/08/NCT00911508/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Between November 2009 and April 2016, 2204, patients with atrial fibrillation from 126 sites across 10 countries, were randomized in equal proportions to either catheter ablation or drug therapy, using permuted block randomization with stratification by clinical site.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Left Atrial Ablation</title>
          <description>All patients randomized to the ablation group were required to undergo left atrial pulmonary vein isolation. The addition of ancillary ablation techniques including linear, ganglion plexus, and electrogram-based approaches were left to the discretion of the investigators.</description>
        </group>
        <group group_id="P2">
          <title>Rate or Rhythm Control Therapy</title>
          <description>All patients randomized to drug therapy, were treated with standard rhythm and/or rate control drugs selected in accordance with contemporary guidelines, according to investigator discretion.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1108"/>
                <participants group_id="P2" count="1096"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1002"/>
                <participants group_id="P2" count="966"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="106"/>
                <participants group_id="P2" count="130"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="79"/>
                <participants group_id="P2" count="112"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Left Atrial Ablation</title>
          <description>All patients randomized to the ablation group were required to undergo left atrial pulmonary vein isolation. The addition of ancillary ablation techniques including linear, ganglion plexus, and electrogram-based approaches were left to the discretion of the investigators.</description>
        </group>
        <group group_id="B2">
          <title>Rate or Rhythm Control Therapy</title>
          <description>All patients randomized to drug therapy, were treated with standard rhythm and/or rate control drugs selected in accordance with contemporary guidelines, according to investigator discretion.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1108"/>
            <count group_id="B2" value="1096"/>
            <count group_id="B3" value="2204"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <title>Age</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="1108"/>
                    <count group_id="B2" value="1096"/>
                    <count group_id="B3" value="2204"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68" lower_limit="62" upper_limit="72"/>
                    <measurement group_id="B2" value="67" lower_limit="62" upper_limit="72"/>
                    <measurement group_id="B3" value="68" lower_limit="62" upper_limit="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="1108"/>
                    <count group_id="B2" value="1096"/>
                    <count group_id="B3" value="2204"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt; 65 years old</title>
                  <measurement_list>
                    <measurement group_id="B1" value="375"/>
                    <measurement group_id="B2" value="391"/>
                    <measurement group_id="B3" value="766"/>
                  </measurement_list>
                </category>
                <category>
                  <title>65 to &lt;75 years old</title>
                  <measurement_list>
                    <measurement group_id="B1" value="577"/>
                    <measurement group_id="B2" value="553"/>
                    <measurement group_id="B3" value="1130"/>
                  </measurement_list>
                </category>
                <category>
                  <title>≥ 75 years old</title>
                  <measurement_list>
                    <measurement group_id="B1" value="156"/>
                    <measurement group_id="B2" value="152"/>
                    <measurement group_id="B3" value="308"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="1108"/>
                    <count group_id="B2" value="1096"/>
                    <count group_id="B3" value="2204"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="413"/>
                    <measurement group_id="B2" value="406"/>
                    <measurement group_id="B3" value="819"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="695"/>
                    <measurement group_id="B2" value="690"/>
                    <measurement group_id="B3" value="1385"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="1108"/>
                    <count group_id="B2" value="1096"/>
                    <count group_id="B3" value="2204"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="84"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="77"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1018"/>
                    <measurement group_id="B2" value="1007"/>
                    <measurement group_id="B3" value="2025"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Canada</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="1108"/>
                    <count group_id="B2" value="1096"/>
                    <count group_id="B3" value="2204"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>South Korea</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="1108"/>
                    <count group_id="B2" value="1096"/>
                    <count group_id="B3" value="2204"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="1108"/>
                    <count group_id="B2" value="1096"/>
                    <count group_id="B3" value="2204"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="625"/>
                    <measurement group_id="B2" value="608"/>
                    <measurement group_id="B3" value="1233"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Czechia</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="1108"/>
                    <count group_id="B2" value="1096"/>
                    <count group_id="B3" value="2204"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>China</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="1108"/>
                    <count group_id="B2" value="1096"/>
                    <count group_id="B3" value="2204"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Italy</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="1108"/>
                    <count group_id="B2" value="1096"/>
                    <count group_id="B3" value="2204"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="1108"/>
                    <count group_id="B2" value="1096"/>
                    <count group_id="B3" value="2204"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Australia</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="1108"/>
                    <count group_id="B2" value="1096"/>
                    <count group_id="B3" value="2204"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="1108"/>
                    <count group_id="B2" value="1096"/>
                    <count group_id="B3" value="2204"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="216"/>
                    <measurement group_id="B2" value="219"/>
                    <measurement group_id="B3" value="435"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Russia</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="1108"/>
                    <count group_id="B2" value="1096"/>
                    <count group_id="B3" value="2204"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="137"/>
                    <measurement group_id="B2" value="139"/>
                    <measurement group_id="B3" value="276"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Atrial fibrillation type at time of enrollment</title>
          <description>Type of AF (paroxysmal = AF episodes lasting ≥1 hour in duration that terminates spontaneously within 7 days or cardioversion is performed within 48h of AF onset; Persistent = AF episode sustained for ≥7 days or cardioversion is performed more than 48h after AF onset; Longstanding Persistent = continuous AF of duration &gt;1 year.</description>
          <population>One patient randomized to Rate or Rhythm Control Therapy withdrew consent on the same day that signed consent was obtained. No baseline or additional data was recorded.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="1108"/>
                    <count group_id="B2" value="1095"/>
                    <count group_id="B3" value="2203"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Paroxysmal</title>
                  <measurement_list>
                    <measurement group_id="B1" value="470"/>
                    <measurement group_id="B2" value="476"/>
                    <measurement group_id="B3" value="946"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Persistent</title>
                  <measurement_list>
                    <measurement group_id="B1" value="524"/>
                    <measurement group_id="B2" value="518"/>
                    <measurement group_id="B3" value="1042"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Long-standing persistent</title>
                  <measurement_list>
                    <measurement group_id="B1" value="114"/>
                    <measurement group_id="B2" value="101"/>
                    <measurement group_id="B3" value="215"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Composite of Total Mortality, Disabling Stroke, Serious Bleeding, or Cardiac Arrest in Patients Warranting Therapy for AF.</title>
        <description>All events for each component of the primary endpoint were reviewed and adjudicated in a blinded fashion by an independent clinical events committee using prospectively determined event definitions. Death was defined as all-cause mortality, disabling stroke (including intracranial bleeding) as an irreversible physical limitation defined by a Rankin Stroke Scale ≥2, and serious bleeding as bleeding accompanied by hemodynamic compromise that required surgical intervention or a transfusion of ≥3 units of blood.</description>
        <time_frame>From date of enrollment until time-to-first event over a median follow-up of 48.5 months.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Left Atrial Ablation</title>
            <description>All patients randomized to the ablation group were required to undergo left atrial pulmonary vein isolation. The addition of ancillary ablation techniques including linear, ganglion plexus, and electrogram-based approaches were left to the discretion of the investigators.</description>
          </group>
          <group group_id="O2">
            <title>Rate or Rhythm Control Therapy</title>
            <description>All patients randomized to drug therapy, were treated with standard rhythm and/or rate control drugs selected in accordance with contemporary guidelines, according to investigator discretion.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Composite of Total Mortality, Disabling Stroke, Serious Bleeding, or Cardiac Arrest in Patients Warranting Therapy for AF.</title>
          <description>All events for each component of the primary endpoint were reviewed and adjudicated in a blinded fashion by an independent clinical events committee using prospectively determined event definitions. Death was defined as all-cause mortality, disabling stroke (including intracranial bleeding) as an irreversible physical limitation defined by a Rankin Stroke Scale ≥2, and serious bleeding as bleeding accompanied by hemodynamic compromise that required surgical intervention or a transfusion of ≥3 units of blood.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1108"/>
                <count group_id="O2" value="1096"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89"/>
                    <measurement group_id="O2" value="101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>0.86</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.65</ci_lower_limit>
            <ci_upper_limit>1.15</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All-cause Mortality</title>
        <description>All deaths were reviewed and adjudicated by the Clinical Events Committee</description>
        <time_frame>From date of enrollment until date of death over a median follow-up of 48.5 months.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Left Atrial Ablation</title>
            <description>All patients randomized to the ablation group were required to undergo left atrial pulmonary vein isolation. The addition of ancillary ablation techniques including linear, ganglion plexus, and electrogram-based approaches were left to the discretion of the investigators.</description>
          </group>
          <group group_id="O2">
            <title>Rate or Rhythm Control Therapy</title>
            <description>All patients randomized to drug therapy, were treated with standard rhythm and/or rate control drugs selected in accordance with contemporary guidelines, according to investigator discretion.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With All-cause Mortality</title>
          <description>All deaths were reviewed and adjudicated by the Clinical Events Committee</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1108"/>
                <count group_id="O2" value="1096"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58"/>
                    <measurement group_id="O2" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>0.85</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.60</ci_lower_limit>
            <ci_upper_limit>1.21</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Mortality or Cardiovascular (CV) Hospitalization</title>
        <description>Hospitalization was characterized by the site principal investigator (PI) and reported as part of the hospitalization case report form.</description>
        <time_frame>From date of enrollment until time-to-first event of death or CV hospitalization over a median follow-up of 48.5 months.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Left Atrial Ablation</title>
            <description>All patients randomized to the ablation group were required to undergo left atrial pulmonary vein isolation. The addition of ancillary ablation techniques including linear, ganglion plexus, and electrogram-based approaches were left to the discretion of the investigators.</description>
          </group>
          <group group_id="O2">
            <title>Rate or Rhythm Control Therapy</title>
            <description>All patients randomized to drug therapy, were treated with standard rhythm and/or rate control drugs selected in accordance with contemporary guidelines, according to investigator discretion.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Mortality or Cardiovascular (CV) Hospitalization</title>
          <description>Hospitalization was characterized by the site principal investigator (PI) and reported as part of the hospitalization case report form.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1108"/>
                <count group_id="O2" value="1096"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="573"/>
                    <measurement group_id="O2" value="637"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>0.83</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.74</ci_lower_limit>
            <ci_upper_limit>0.93</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Mortality, Disabling Stroke, or CV Hospitalization (for Heart Failure or Acute Ischemic Events)</title>
        <description>Disabling stroke (including intracranial bleeding) was defined as an irreversible physical limitation defined by a Rankin Stroke Scale ≥2 and the reason for hospitalization was characterized by the site PI and reported as part of the hospitalization case report form.</description>
        <time_frame>From date of enrollment until time-to-first event of death, stroke, or CV hospitalization (for heart failure or acute ischemic event) over a median follow-up of 48.5 months.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Left Atrial Ablation</title>
            <description>All patients randomized to the ablation group were required to undergo left atrial pulmonary vein isolation. The addition of ancillary ablation techniques including linear, ganglion plexus, and electrogram-based approaches were left to the discretion of the investigators.</description>
          </group>
          <group group_id="O2">
            <title>Rate or Rhythm Control Therapy</title>
            <description>All patients randomized to drug therapy, were treated with standard rhythm and/or rate control drugs selected in accordance with contemporary guidelines, according to investigator discretion.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Mortality, Disabling Stroke, or CV Hospitalization (for Heart Failure or Acute Ischemic Events)</title>
          <description>Disabling stroke (including intracranial bleeding) was defined as an irreversible physical limitation defined by a Rankin Stroke Scale ≥2 and the reason for hospitalization was characterized by the site PI and reported as part of the hospitalization case report form.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1108"/>
                <count group_id="O2" value="1096"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="170"/>
                    <measurement group_id="O2" value="189"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>0.88</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.72</ci_lower_limit>
            <ci_upper_limit>1.09</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Cardiovascular Death</title>
        <description>Cardiovascular death as determined by the Clinical Events Committee based on the available data provided by the Principal Investigator</description>
        <time_frame>From date of enrollment until date of a cardiovascular death over a median follow-up of 48.5 months.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Left Atrial Ablation</title>
            <description>All patients randomized to the ablation group were required to undergo left atrial pulmonary vein isolation. The addition of ancillary ablation techniques including linear, ganglion plexus, and electrogram-based approaches were left to the discretion of the investigators.</description>
          </group>
          <group group_id="O2">
            <title>Rate or Rhythm Control Therapy</title>
            <description>All patients randomized to drug therapy, were treated with standard rhythm and/or rate control drugs selected in accordance with contemporary guidelines, according to investigator discretion.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Cardiovascular Death</title>
          <description>Cardiovascular death as determined by the Clinical Events Committee based on the available data provided by the Principal Investigator</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1108"/>
                <count group_id="O2" value="1096"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>0.94</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.53</ci_lower_limit>
            <ci_upper_limit>1.68</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Cardiovascular Death or Disabling Stroke</title>
        <description>Disabling stroke (including intracranial bleeding) was defined as an irreversible physical limitation defined by a Rankin Stroke Scale ≥2.</description>
        <time_frame>From date of enrollment until time-to-first event of a cardiovascular death or disabling stroke over a median follow-up of 48.5 months.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Left Atrial Ablation</title>
            <description>All patients randomized to the ablation group were required to undergo left atrial pulmonary vein isolation. The addition of ancillary ablation techniques including linear, ganglion plexus, and electrogram-based approaches were left to the discretion of the investigators.</description>
          </group>
          <group group_id="O2">
            <title>Rate or Rhythm Control Therapy</title>
            <description>All patients randomized to drug therapy, were treated with standard rhythm and/or rate control drugs selected in accordance with contemporary guidelines, according to investigator discretion.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Cardiovascular Death or Disabling Stroke</title>
          <description>Disabling stroke (including intracranial bleeding) was defined as an irreversible physical limitation defined by a Rankin Stroke Scale ≥2.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1108"/>
                <count group_id="O2" value="1096"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>0.87</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.51</ci_lower_limit>
            <ci_upper_limit>1.51</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With an Arrhythmic Death or Cardiac Arrest</title>
        <description>All deaths and cardiac arrest events were adjudicated by the Clinical Events Committee</description>
        <time_frame>From date of enrollment until time-to-first event for an arrhythmic death or cardiac arrest over a median follow-up of 48.5 months.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Left Atrial Ablation</title>
            <description>All patients randomized to the ablation group were required to undergo left atrial pulmonary vein isolation. The addition of ancillary ablation techniques including linear, ganglion plexus, and electrogram-based approaches were left to the discretion of the investigators.</description>
          </group>
          <group group_id="O2">
            <title>Rate or Rhythm Control Therapy</title>
            <description>All patients randomized to drug therapy, were treated with standard rhythm and/or rate control drugs selected in accordance with contemporary guidelines, according to investigator discretion.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With an Arrhythmic Death or Cardiac Arrest</title>
          <description>All deaths and cardiac arrest events were adjudicated by the Clinical Events Committee</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1108"/>
                <count group_id="O2" value="1096"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>0.76</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.33</ci_lower_limit>
            <ci_upper_limit>1.72</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Heart Failure Death</title>
        <description>All deaths were categorized and adjudicated by the Clinical Events Committee</description>
        <time_frame>From date of enrollment until date of heart failure death over a median follow-up of 48.5 months.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Left Atrial Ablation</title>
            <description>All patients randomized to the ablation group were required to undergo left atrial pulmonary vein isolation. The addition of ancillary ablation techniques including linear, ganglion plexus, and electrogram-based approaches were left to the discretion of the investigators.</description>
          </group>
          <group group_id="O2">
            <title>Rate or Rhythm Control Therapy</title>
            <description>All patients randomized to drug therapy, were treated with standard rhythm and/or rate control drugs selected in accordance with contemporary guidelines, according to investigator discretion.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Heart Failure Death</title>
          <description>All deaths were categorized and adjudicated by the Clinical Events Committee</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1108"/>
                <count group_id="O2" value="1096"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>1.13</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.41</ci_lower_limit>
            <ci_upper_limit>3.09</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Free From Recurrent Atrial Fibrillation (AF) Following the 90 Day Blanking Period</title>
        <description>Data from patients using the study provided ECG event recording system were analyzed. A 30-second episode of AF in either group, confirmed through blinded review by an ECG Core Lab Committee was used for defining the endpoint of recurrent AF.</description>
        <time_frame>From date of therapy initiation until date of first AF recurrence following a 90 day wait (blanking) period over a median follow-up of 48.5 months.</time_frame>
        <population>Subjects were analyzed in the post-blanking period if randomized treatment occurred and the subject did not die, withdraw, or get lost to follow-up before the end of the 90 day blanking period.</population>
        <group_list>
          <group group_id="O1">
            <title>Left Atrial Ablation</title>
            <description>All patients randomized to the ablation group were required to undergo left atrial pulmonary vein isolation. The addition of ancillary ablation techniques including linear, ganglion plexus, and electrogram-based approaches were left to the discretion of the investigators.</description>
          </group>
          <group group_id="O2">
            <title>Rate or Rhythm Control Therapy</title>
            <description>All patients randomized to drug therapy, were treated with standard rhythm and/or rate control drugs selected in accordance with contemporary guidelines, according to investigator discretion.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Free From Recurrent Atrial Fibrillation (AF) Following the 90 Day Blanking Period</title>
          <description>Data from patients using the study provided ECG event recording system were analyzed. A 30-second episode of AF in either group, confirmed through blinded review by an ECG Core Lab Committee was used for defining the endpoint of recurrent AF.</description>
          <population>Subjects were analyzed in the post-blanking period if randomized treatment occurred and the subject did not die, withdraw, or get lost to follow-up before the end of the 90 day blanking period.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="611"/>
                <count group_id="O2" value="629"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="305"/>
                    <measurement group_id="O2" value="437"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>0.52</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.45</ci_lower_limit>
            <ci_upper_limit>0.60</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Cardiovascular Hospitalization</title>
        <description>The reason for hospitalization was characterized by the site PI and reported as part of the hospitalization case report form.</description>
        <time_frame>From date of enrollment until date of cardiovascular hospitalization over a median follow-up of 48.5 months.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Left Atrial Ablation</title>
            <description>All patients randomized to the ablation group were required to undergo left atrial pulmonary vein isolation. The addition of ancillary ablation techniques including linear, ganglion plexus, and electrogram-based approaches were left to the discretion of the investigators.</description>
          </group>
          <group group_id="O2">
            <title>Rate or Rhythm Control Therapy</title>
            <description>All patients randomized to drug therapy, were treated with standard rhythm and/or rate control drugs selected in accordance with contemporary guidelines, according to investigator discretion.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Cardiovascular Hospitalization</title>
          <description>The reason for hospitalization was characterized by the site PI and reported as part of the hospitalization case report form.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1108"/>
                <count group_id="O2" value="1096"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="556"/>
                    <measurement group_id="O2" value="605"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>0.86</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.77</ci_lower_limit>
            <ci_upper_limit>0.97</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Quality of Life Measures - AFEQT</title>
        <description>Atrial Fibrillation Effect on Quality of Life (AFEQT) Overall Score (Scale: 0 = complete disability, 100 = no disability). The AFEQT is a 21-item AF-specific, health-related QOL questionnaire designed to assess the effect of atrial fibrillation on patient quality of life. The AFEQT has an Overall Score (calculated from 18 of the questions) and subscale scores in three domains: symptoms, daily activities, and treatment concern. Overall and subscale scores range from 0 (corresponds to complete disability) to 100 (no AF-related disability).</description>
        <time_frame>Baseline ,12 month, 5 years</time_frame>
        <population>Only patients with questionnaire data were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Left Atrial Ablation</title>
            <description>All patients randomized to the ablation group were required to undergo left atrial pulmonary vein isolation. The addition of ancillary ablation techniques including linear, ganglion plexus, and electrogram-based approaches were left to the discretion of the investigators.</description>
          </group>
          <group group_id="O2">
            <title>Rate or Rhythm Control Therapy</title>
            <description>All patients randomized to drug therapy, were treated with standard rhythm and/or rate control drugs selected in accordance with contemporary guidelines, according to investigator discretion.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Quality of Life Measures - AFEQT</title>
          <description>Atrial Fibrillation Effect on Quality of Life (AFEQT) Overall Score (Scale: 0 = complete disability, 100 = no disability). The AFEQT is a 21-item AF-specific, health-related QOL questionnaire designed to assess the effect of atrial fibrillation on patient quality of life. The AFEQT has an Overall Score (calculated from 18 of the questions) and subscale scores in three domains: symptoms, daily activities, and treatment concern. Overall and subscale scores range from 0 (corresponds to complete disability) to 100 (no AF-related disability).</description>
          <population>Only patients with questionnaire data were analyzed.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1084"/>
                <count group_id="O2" value="1078"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1084"/>
                    <count group_id="O2" value="1078"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.9" spread="20.5"/>
                    <measurement group_id="O2" value="63.1" spread="20.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 Month</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="915"/>
                    <count group_id="O2" value="903"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.4" spread="16.5"/>
                    <measurement group_id="O2" value="80.9" spread="18.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 Year</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="329"/>
                    <count group_id="O2" value="320"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.2" spread="16.2"/>
                    <measurement group_id="O2" value="83.3" spread="18.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>12 Month</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>5.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.7</ci_lower_limit>
            <ci_upper_limit>6.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>5 Years</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>3.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.1</ci_lower_limit>
            <ci_upper_limit>4.8</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Quality of Life Measures - MAFSI Frequency Score</title>
        <description>The Mayo AF-Specific Symptom Inventory (MAFSI) is a questionnaire comprised of a 10-item AF symptom checklist that asked about both the frequency and severity of each symptom. MAFSI frequency of symptoms over the past month was recorded as 0 (never), 1 (rarely), 2 (sometimes), 3 (often), and 4 (always) for each of the 10 items listed in the questionnaire. The 10 item responses were summed for a total Frequency Score that ranged from 0 (no AF symptoms) to 40 (worst score).</description>
        <time_frame>Baseline, 12 Month, 5 Year</time_frame>
        <population>Only patients with questionnaire data were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Left Atrial Ablation</title>
            <description>All patients randomized to the ablation group were required to undergo left atrial pulmonary vein isolation. The addition of ancillary ablation techniques including linear, ganglion plexus, and electrogram-based approaches were left to the discretion of the investigators.</description>
          </group>
          <group group_id="O2">
            <title>Rate or Rhythm Control Therapy</title>
            <description>All patients randomized to drug therapy, were treated with standard rhythm and/or rate control drugs selected in accordance with contemporary guidelines, according to investigator discretion.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Quality of Life Measures - MAFSI Frequency Score</title>
          <description>The Mayo AF-Specific Symptom Inventory (MAFSI) is a questionnaire comprised of a 10-item AF symptom checklist that asked about both the frequency and severity of each symptom. MAFSI frequency of symptoms over the past month was recorded as 0 (never), 1 (rarely), 2 (sometimes), 3 (often), and 4 (always) for each of the 10 items listed in the questionnaire. The 10 item responses were summed for a total Frequency Score that ranged from 0 (no AF symptoms) to 40 (worst score).</description>
          <population>Only patients with questionnaire data were analyzed.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1069"/>
                <count group_id="O2" value="1061"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1069"/>
                    <count group_id="O2" value="1061"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.8" spread="6.2"/>
                    <measurement group_id="O2" value="11.9" spread="6.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 Month</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="828"/>
                    <count group_id="O2" value="831"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.4" spread="6.0"/>
                    <measurement group_id="O2" value="8.1" spread="6.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 Year</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="279"/>
                    <count group_id="O2" value="295"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.8" spread="5.7"/>
                    <measurement group_id="O2" value="7.0" spread="6.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>12 Month</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-1.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.3</ci_lower_limit>
            <ci_upper_limit>-1.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>5 Year</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-1.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.9</ci_lower_limit>
            <ci_upper_limit>-0.9</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Quality of Life Measures - MAFSI Severity Score</title>
        <description>The Mayo AF-Specific Symptom Inventory (MAFSI) is a questionnaire comprised of a 10-item AF symptom checklist that asked about both the frequency and severity of each symptom. MAFSI severity scores over the past month were recorded as 1 (mild), 2 (moderate), and 3 (extreme) for each of the 10 items listed in the questionnaire. The 10 items items were then summed for the total Severity Score that ranged from 0 (no AF symptoms) to 30 (most severe AF symptoms).</description>
        <time_frame>Baseline, 12 Month, 5 Year</time_frame>
        <population>Only patients with questionnaire data were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Left Atrial Ablation</title>
            <description>All patients randomized to the ablation group were required to undergo left atrial pulmonary vein isolation. The addition of ancillary ablation techniques including linear, ganglion plexus, and electrogram-based approaches were left to the discretion of the investigators.</description>
          </group>
          <group group_id="O2">
            <title>Rate or Rhythm Control Therapy</title>
            <description>All patients randomized to drug therapy, were treated with standard rhythm and/or rate control drugs selected in accordance with contemporary guidelines, according to investigator discretion.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Quality of Life Measures - MAFSI Severity Score</title>
          <description>The Mayo AF-Specific Symptom Inventory (MAFSI) is a questionnaire comprised of a 10-item AF symptom checklist that asked about both the frequency and severity of each symptom. MAFSI severity scores over the past month were recorded as 1 (mild), 2 (moderate), and 3 (extreme) for each of the 10 items listed in the questionnaire. The 10 items items were then summed for the total Severity Score that ranged from 0 (no AF symptoms) to 30 (most severe AF symptoms).</description>
          <population>Only patients with questionnaire data were analyzed.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1066"/>
                <count group_id="O2" value="1056"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1066"/>
                    <count group_id="O2" value="1056"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.3" spread="4.9"/>
                    <measurement group_id="O2" value="9.3" spread="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 Month</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="827"/>
                    <count group_id="O2" value="830"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0" spread="4.7"/>
                    <measurement group_id="O2" value="6.5" spread="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 year</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="279"/>
                    <count group_id="O2" value="295"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.6" spread="4.7"/>
                    <measurement group_id="O2" value="5.6" spread="4.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>12 Month</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-1.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.0</ci_lower_limit>
            <ci_upper_limit>-1.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>5 Year</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-1.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.7</ci_lower_limit>
            <ci_upper_limit>-0.4</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Events/Complications</title>
        <description>Comparing individual non-endpoint adverse events between ablative and drug therapy is difficult due to the substantial difference in the types of adverse events expected.
Ablation-related events were counted among all patients that were randomized to and received an ablation.
Drug-related events were counted among all patients that were randomized to and received drug therapy.</description>
        <time_frame>From treatment start date to date of event over a median follow-up of 48.5 months.</time_frame>
        <population>Ablation-related events were counted among all patients that were randomized to and received an ablation.
Drug-related events were counted among all patients that were randomized to and received drug therapy.</population>
        <group_list>
          <group group_id="O1">
            <title>Left Atrial Ablation</title>
            <description>All patients randomized to the ablation group were required to undergo left atrial pulmonary vein isolation. The addition of ancillary ablation techniques including linear, ganglion plexus, and electrogram-based approaches were left to the discretion of the investigators.</description>
          </group>
          <group group_id="O2">
            <title>Rate or Rhythm Control Therapy</title>
            <description>All patients randomized to drug therapy, were treated with standard rhythm and/or rate control drugs selected in accordance with contemporary guidelines, according to investigator discretion.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events/Complications</title>
          <description>Comparing individual non-endpoint adverse events between ablative and drug therapy is difficult due to the substantial difference in the types of adverse events expected.
Ablation-related events were counted among all patients that were randomized to and received an ablation.
Drug-related events were counted among all patients that were randomized to and received drug therapy.</description>
          <population>Ablation-related events were counted among all patients that were randomized to and received an ablation.
Drug-related events were counted among all patients that were randomized to and received drug therapy.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1006"/>
                <count group_id="O2" value="1092"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hyper- or hyopthyroidism</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypotension</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Major proarrhythmic event (VT, VF)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Atrial proarrhythmic event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Allergic reaction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gastrointestinal abnormality (excluding &gt;moderate)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Liver injury/failure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pulmonary toxicity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hematoma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pseudo aneurysm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Atrial venous fistula</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pneumothorax</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sepsis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cardiac tamponade with perforation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Transient ischemic attack (TIA)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myocardial infarction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe pericardial chest pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phrenic nerve injury</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pulmonary vein stenosis &gt;75%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Esophageal ulcer</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected from time of enrollment through study completion over a median follow-up duration of 48.5 months.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Left Atrial Ablation</title>
          <description>All patients randomized to the ablation group were required to undergo left atrial pulmonary vein isolation. The addition of ancillary ablation techniques including linear, ganglion plexus, and electrogram-based approaches were left to the discretion of the investigators.</description>
        </group>
        <group group_id="E2">
          <title>Rate or Rhythm Control Therapy</title>
          <description>All patients randomized to drug therapy, were treated with standard rhythm and/or rate control drugs selected in accordance with contemporary guidelines, according to investigator discretion.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="58" subjects_at_risk="1108"/>
                <counts group_id="E2" subjects_affected="67" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="454" subjects_at_risk="1108"/>
                <counts group_id="E2" subjects_affected="430" subjects_at_risk="1096"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>ANAEMIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>ANAEMIA OF MALIGNANT DISEASE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>AUTOIMMUNE HAEMOLYTIC ANAEMIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>FEBRILE NEUTROPENIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>HAEMORRHAGIC DISORDER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>IMMUNE THROMBOCYTOPENIC PURPURA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>IRON DEFICIENCY ANAEMIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>THROMBOCYTOPENIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1108"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1096"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>ACUTE CORONARY SYNDROME</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>ACUTE MYOCARDIAL INFARCTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>ANGINA PECTORIS</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="1108"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>ANGINA UNSTABLE</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1108"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>AORTIC VALVE INCOMPETENCE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>AORTIC VALVE STENOSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>ARRHYTHMIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>ARTERIOSCLEROSIS CORONARY ARTERY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1108"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>ATRIAL FLUTTER</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="1108"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>ATRIAL SEPTAL DEFECT ACQUIRED</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>ATRIAL TACHYCARDIA</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="1108"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>ATRIAL THROMBOSIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>ATRIOVENTRICULAR BLOCK</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="1108"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>ATRIOVENTRICULAR BLOCK COMPLETE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>ATRIOVENTRICULAR BLOCK SECOND DEGREE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>BRADYCARDIA</sub_title>
                <counts group_id="E1" events="18" subjects_affected="18" subjects_at_risk="1108"/>
                <counts group_id="E2" events="28" subjects_affected="25" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>BUNDLE BRANCH BLOCK LEFT</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>CARDIAC ARREST</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="1108"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>CARDIAC FAILURE</sub_title>
                <counts group_id="E1" events="90" subjects_affected="60" subjects_at_risk="1108"/>
                <counts group_id="E2" events="77" subjects_affected="47" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>CARDIAC FAILURE ACUTE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>CARDIAC FAILURE CHRONIC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>CARDIAC FAILURE CONGESTIVE</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1108"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>CARDIAC PERFORATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>CARDIAC TAMPONADE</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>CARDIAC VALVE DISEASE</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1108"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>CARDIAC VENTRICULAR THROMBOSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>CARDIOGENIC SHOCK</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>CARDIOMYOPATHY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>CORONARY ARTERY DISEASE</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="1108"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>CORONARY ARTERY EMBOLISM</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>CORONARY ARTERY OCCLUSION</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="1108"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>CORONARY ARTERY STENOSIS</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>INTRACARDIAC THROMBUS</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="1108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>LEFT VENTRICULAR DYSFUNCTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1108"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>MITRAL VALVE INCOMPETENCE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>MITRAL VALVE STENOSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>MYOCARDIAL INFARCTION</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="1108"/>
                <counts group_id="E2" events="20" subjects_affected="18" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>MYOCARDIAL ISCHAEMIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>MYOCARDITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>PALPITATIONS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>PERICARDIAL EFFUSION</sub_title>
                <counts group_id="E1" events="24" subjects_affected="22" subjects_at_risk="1108"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>PERICARDITIS</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="1108"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>PERICARDITIS CONSTRICTIVE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>SINOATRIAL BLOCK</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1108"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>SINUS ARREST</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>SINUS BRADYCARDIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>SINUS NODE DYSFUNCTION</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="1108"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>TACHYARRHYTHMIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>TACHYCARDIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>TACHYCARDIA INDUCED CARDIOMYOPATHY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>TRICUSPID VALVE DISEASE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>VENTRICULAR ARRHYTHMIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>VENTRICULAR EXTRASYSTOLES</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1108"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>VENTRICULAR FIBRILLATION</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1108"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>VENTRICULAR TACHYCARDIA</sub_title>
                <counts group_id="E1" events="13" subjects_affected="11" subjects_at_risk="1108"/>
                <counts group_id="E2" events="11" subjects_affected="9" subjects_at_risk="1096"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>ATRIAL SEPTAL DEFECT</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>HYDROCELE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>HYPERTROPHIC CARDIOMYOPATHY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>MUSCULAR DYSTROPHY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>PATENT DUCTUS ARTERIOSUS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>DEAFNESS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>DEAFNESS UNILATERAL</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>SUDDEN HEARING LOSS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>TYMPANIC MEMBRANE PERFORATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>VERTIGO POSITIONAL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>VESTIBULAR DISORDER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1096"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>HYPERTHYROIDISM</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1108"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>HYPOTHYROIDISM</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1108"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1096"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>CATARACT</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1108"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>CATARACT NUCLEAR</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>DIPLOPIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>MACULAR FIBROSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>OPTIC NERVE DISORDER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>RETINAL ARTERY OCCLUSION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>RETINAL DETACHMENT</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>VITREOUS HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1096"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL HERNIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>ABDOMINAL HERNIA OBSTRUCTIVE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN LOWER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>ABDOMINAL WALL HAEMATOMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>ALCOHOLIC PANCREATITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>COLITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1108"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>COLITIS ISCHAEMIC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>CONSTIPATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1108"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>CROHN'S DISEASE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1108"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>DUODENAL ULCER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>DUODENAL ULCER PERFORATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>EROSIVE OESOPHAGITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>FAECAL INCONTINENCE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>GASTRIC DISORDER</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="1108"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>GASTRIC HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>GASTRITIS</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="1108"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>GASTROOESOPHAGEAL REFLUX DISEASE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>HAEMATEMESIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>HAEMORRHOIDAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>HAEMORRHOIDS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>HIATUS HERNIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>ILEUS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>INGUINAL HERNIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1108"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>INGUINAL HERNIA STRANGULATED</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>INTESTINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1108"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>INTESTINAL ISCHAEMIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>INTESTINAL MASS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>INTESTINAL OBSTRUCTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>LOWER GASTROINTESTINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1108"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>MALLORY-WEISS SYNDROME</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>MELAENA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>OESOPHAGEAL DISORDER</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>OESOPHAGITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>PANCREATIC PSEUDOCYST</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>PANCREATITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>PANCREATITIS ACUTE</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>PANCREATITIS RELAPSING</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>PERITONEAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>PNEUMOPERITONEUM</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>RECTAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1108"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>RECTAL PROLAPSE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>RECTAL ULCER HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>SMALL INTESTINAL OBSTRUCTION</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1108"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>SMALL INTESTINAL ULCER HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>SUBILEUS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>TONGUE GEOGRAPHIC</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>UPPER GASTROINTESTINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="1108"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1096"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>ADVERSE DRUG REACTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>CARDIAC DEATH</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>CHEST DISCOMFORT</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>CHEST PAIN</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1108"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>DEATH</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="1108"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>DEVICE MALFUNCTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>FATIGUE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>GAIT DISTURBANCE</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="1108"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>HERNIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>IMPAIRED HEALING</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>MEDICAL DEVICE COMPLICATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>NON-CARDIAC CHEST PAIN</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="1108"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>PAIN</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>STENT-GRAFT ENDOLEAK</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1108"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1096"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>ACUTE HEPATIC FAILURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>BILE DUCT STONE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>CHOLECYSTITIS</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>CHOLECYSTITIS ACUTE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>CHOLELITHIASIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>CHRONIC HEPATITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>HEPATIC CIRRHOSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>HEPATIC FAILURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>NON-ALCOHOLIC STEATOHEPATITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>ANAPHYLACTIC SHOCK</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>HYPERSENSITIVITY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1096"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>ABSCESS LIMB</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>ABSCESS SOFT TISSUE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>ANAL ABSCESS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>ANORECTAL INFECTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>APPENDICITIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>BACTERAEMIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>BRONCHITIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>CELLULITIS</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="1108"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>CHOLECYSTITIS INFECTIVE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>DEVICE RELATED INFECTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>DIABETIC FOOT INFECTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>DIABETIC GANGRENE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>DIVERTICULITIS</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1108"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>ERYSIPELAS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1108"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS CLOSTRIDIAL</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS VIRAL</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>HAEMOPHILUS INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>INFECTION</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="1108"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>INFLUENZA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>LUNG ABSCESS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>LYME DISEASE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1108"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>MEDICAL DEVICE SITE INFECTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>NASOPHARYNGITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>OSTEOMYELITIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>PNEUMONIA</sub_title>
                <counts group_id="E1" events="37" subjects_affected="32" subjects_at_risk="1108"/>
                <counts group_id="E2" events="34" subjects_affected="29" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>PNEUMONIA BACTERIAL</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>POST PROCEDURAL CELLULITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>POSTOPERATIVE WOUND INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>PULMONARY TUBERCULOSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>PYELONEPHRITIS</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>SALMONELLA BACTERAEMIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>SALMONELLOSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>SEPSIS</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="1108"/>
                <counts group_id="E2" events="12" subjects_affected="11" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>SEPTIC SHOCK</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>STAPHYLOCOCCAL BACTERAEMIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>STAPHYLOCOCCAL INFECTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>STREPTOCOCCAL BACTERAEMIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>STREPTOCOCCAL SEPSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="1108"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>UROSEPSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>VULVAL ABSCESS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1096"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>ACCIDENTAL OVERDOSE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>ANASTOMOTIC LEAK</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>ANKLE FRACTURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>BRAIN CONTUSION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>BURN OESOPHAGEAL</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="1108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>CONCUSSION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>CONTRAST MEDIA REACTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>CONTUSION</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>CRANIOCEREBRAL INJURY</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>FALL</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>FEMORAL NECK FRACTURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>FEMUR FRACTURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>FIBULA FRACTURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>FOOT FRACTURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>GUN SHOT WOUND</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>HAND FRACTURE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>HEAD INJURY</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>HEAT EXHAUSTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>HIP FRACTURE</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>HUMERUS FRACTURE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>INCISIONAL HERNIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1108"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>INJURY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>LACERATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1108"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>MENTAL STATUS CHANGES POSTOPERATIVE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>NERVE INJURY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>PATELLA FRACTURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>PELVIC FRACTURE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>POST CONCUSSION SYNDROME</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>POST PROCEDURAL COMPLICATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>POST PROCEDURAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>POSTOPERATIVE ILEUS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>RADIATION SKIN INJURY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>RADIUS FRACTURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>RIB FRACTURE</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>ROAD TRAFFIC ACCIDENT</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>SPINAL COMPRESSION FRACTURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>SPLENIC RUPTURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>SUBDURAL HAEMATOMA</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="1108"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>TENDON RUPTURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>THORACIC VERTEBRAL FRACTURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>TIBIA FRACTURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>TOXICITY TO VARIOUS AGENTS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>TRAUMATIC HAEMATOMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>VASCULAR PSEUDOANEURYSM</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="1108"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>WOUND</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>WRIST FRACTURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1096"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>ANTICOAGULATION DRUG LEVEL ABOVE THERAPEUTIC</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>BLOOD BICARBONATE DECREASED</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>BODY TEMPERATURE INCREASED</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1108"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>ELECTROCARDIOGRAM QT PROLONGED</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>INTERNATIONAL NORMALISED RATIO ABNORMAL</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>LIVER FUNCTION TEST ABNORMAL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>DEHYDRATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>DIABETES MELLITUS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>DIABETES MELLITUS INADEQUATE CONTROL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1108"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>DIABETIC KETOACIDOSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>FAILURE TO THRIVE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>FLUID OVERLOAD</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="1108"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>GOUT</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>HYPERGLYCAEMIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>HYPOGLYCAEMIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>HYPOKALAEMIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>HYPONATRAEMIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>MALNUTRITION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>METABOLIC ACIDOSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>OBESITY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1108"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>TYPE 2 DIABETES MELLITUS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ARTHRITIS</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="1108"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>BONE DISORDER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>BURSITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>CHONDROCALCINOSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>CHONDROCALCINOSIS PYROPHOSPHATE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>CHONDROPATHY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>COSTOCHONDRITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>GOUTY ARTHRITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>GOUTY TOPHUS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>HAEMARTHROSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>INTERVERTEBRAL DISC PROTRUSION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>MUSCLE DISORDER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>MUSCULAR WEAKNESS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>MUSCULOSKELETAL CHEST PAIN</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>MUSCULOSKELETAL PAIN</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>NECK PAIN</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>OSTEOARTHRITIS</sub_title>
                <counts group_id="E1" events="21" subjects_affected="18" subjects_at_risk="1108"/>
                <counts group_id="E2" events="28" subjects_affected="24" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>OSTEOCHONDROSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>OSTEOPOROTIC FRACTURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>PAIN IN EXTREMITY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>RHEUMATOID ARTHRITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>ROTATOR CUFF SYNDROME</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1108"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>SCLERODERMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>SCOLIOSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>SPINAL COLUMN STENOSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>SPONDYLOLISTHESIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>ACUTE MYELOID LEUKAEMIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>ANOGENITAL WARTS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>APPENDIX CANCER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>B-CELL LYMPHOMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>BASAL CELL CARCINOMA</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1108"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>BLADDER CANCER</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>BLADDER NEOPLASM</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>BLADDER TRANSITIONAL CELL CARCINOMA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>BLADDER TRANSITIONAL CELL CARCINOMA RECURRENT</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>BRAIN CANCER METASTATIC</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>BREAST CANCER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>CHOLANGIOCARCINOMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>CHOLESTEATOMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>CHRONIC LYMPHOCYTIC LEUKAEMIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>CHRONIC MYELOID LEUKAEMIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>COLON ADENOMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>COLON CANCER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>DIFFUSE LARGE B-CELL LYMPHOMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>GASTRIC CANCER</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>INVASIVE LOBULAR BREAST CARCINOMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>LARGE INTESTINE BENIGN NEOPLASM</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>LIPOMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>LUNG ADENOCARCINOMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>LUNG CANCER METASTATIC</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>LUNG CARCINOMA CELL TYPE UNSPECIFIED RECURRENT</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>LUNG CARCINOMA CELL TYPE UNSPECIFIED STAGE III</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>LUNG NEOPLASM MALIGNANT</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1108"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>LYMPHOMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>MALIGNANT MELANOMA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1108"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>MALIGNANT PERITONEAL NEOPLASM</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>METASTASES TO LIVER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>METASTASES TO LUNG</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>METASTATIC GASTRIC CANCER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>METASTATIC MALIGNANT MELANOMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1108"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>METASTATIC NEOPLASM</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="1108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>MYELODYSPLASTIC SYNDROME</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>NEUROENDOCRINE CARCINOMA METASTATIC</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>NON-SMALL CELL LUNG CANCER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>OESOPHAGEAL ADENOCARCINOMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>OESOPHAGEAL CARCINOMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>OVARIAN ADENOMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>PANCREATIC CARCINOMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>PLASMA CELL MYELOMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>PROSTATE CANCER</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="1108"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>PROSTATE CANCER METASTATIC</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1108"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>PROSTATE CANCER STAGE III</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>RECTAL CANCER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1108"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>RENAL CANCER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>SALIVARY GLAND NEOPLASM</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>SQUAMOUS CELL CARCINOMA</sub_title>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>SQUAMOUS CELL CARCINOMA OF SKIN</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>SQUAMOUS CELL CARCINOMA OF THE ORAL CAVITY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>THROAT CANCER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>THYROID ADENOMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>TRANSITIONAL CELL CARCINOMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>ALTERED STATE OF CONSCIOUSNESS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>CAROTID ARTERIOSCLEROSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>CAROTID ARTERY OCCLUSION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>CAROTID ARTERY STENOSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>CARPAL TUNNEL SYNDROME</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>CEREBRAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1108"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>CEREBROVASCULAR ACCIDENT</sub_title>
                <counts group_id="E1" events="22" subjects_affected="22" subjects_at_risk="1108"/>
                <counts group_id="E2" events="39" subjects_affected="33" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>CERVICAL MYELOPATHY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1108"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>DEMENTIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>DEMENTIA ALZHEIMER'S TYPE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>DIZZINESS</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="1108"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>DYSARTHRIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>ENCEPHALOPATHY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>EPILEPSY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1108"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>HAEMORRHAGE INTRACRANIAL</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1108"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>HAEMORRHAGIC STROKE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>HYPERTONIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>METABOLIC ENCEPHALOPATHY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>MYELOPATHY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>NERVOUS SYSTEM DISORDER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>PARKINSON'S DISEASE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>PHRENIC NERVE PARALYSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>POLYNEUROPATHY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>POST-INJECTION DELIRIUM SEDATION SYNDROME</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>PRESYNCOPE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1108"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>RADICULOPATHY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>SCIATICA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1108"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>SEIZURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>SPINAL CORD DISORDER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>SPINAL CORD HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>SUBARACHNOID HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1108"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>SYNCOPE</sub_title>
                <counts group_id="E1" events="17" subjects_affected="15" subjects_at_risk="1108"/>
                <counts group_id="E2" events="22" subjects_affected="19" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>TRANSIENT ISCHAEMIC ATTACK</sub_title>
                <counts group_id="E1" events="20" subjects_affected="20" subjects_at_risk="1108"/>
                <counts group_id="E2" events="21" subjects_affected="19" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>TRIGEMINAL NEURITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>UNRESPONSIVE TO STIMULI</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>VIITH NERVE PARALYSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1096"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>DEVICE BATTERY ISSUE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>DEVICE DAMAGE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>DEVICE DISLOCATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>DEVICE INAPPROPRIATE SHOCK DELIVERY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>DEVICE ISSUE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>DEVICE OCCLUSION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>THROMBOSIS IN DEVICE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>ANXIETY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>COMPLETED SUICIDE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>DELIRIUM</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>MAJOR DEPRESSION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>MENTAL STATUS CHANGES</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>SUICIDE ATTEMPT</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1096"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>ACUTE KIDNEY INJURY</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1108"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>CALCULUS BLADDER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>CALCULUS URETERIC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>HAEMATURIA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1108"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>HYDRONEPHROSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>NEPHROLITHIASIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1108"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>NEPHROTIC SYNDROME</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>RENAL ARTERY STENOSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>RENAL COLIC</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>RENAL FAILURE</sub_title>
                <counts group_id="E1" events="18" subjects_affected="16" subjects_at_risk="1108"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>RENAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>RENAL IMPAIRMENT</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>RENAL MASS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>TUBULOINTERSTITIAL NEPHRITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>URETEROLITHIASIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>URETHRAL CYST</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>URETHRAL STENOSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1108"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>URINARY INCONTINENCE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>URINARY RETENTION</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>BENIGN PROSTATIC HYPERPLASIA</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>FEMALE GENITAL TRACT FISTULA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1108"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>OVARIAN MASS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>PELVIC FLUID COLLECTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>POSTMENOPAUSAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>PROSTATOMEGALY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>VAGINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>ACUTE RESPIRATORY DISTRESS SYNDROME</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>ACUTE RESPIRATORY FAILURE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>ASTHMA</sub_title>
                <counts group_id="E1" events="8" subjects_affected="2" subjects_at_risk="1108"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>CHRONIC OBSTRUCTIVE PULMONARY DISEASE</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1108"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>CHRONIC RESPIRATORY FAILURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>DYSPHONIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>DYSPNOEA</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="1108"/>
                <counts group_id="E2" events="12" subjects_affected="11" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>DYSPNOEA EXERTIONAL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1108"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>EPISTAXIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>HAEMOPTYSIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>HAEMOTHORAX</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>INTERSTITIAL LUNG DISEASE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>PLEURAL EFFUSION</sub_title>
                <counts group_id="E1" events="12" subjects_affected="8" subjects_at_risk="1108"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>PLEURITIC PAIN</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>PNEUMOTHORAX</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>PULMONARY CONGESTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>PULMONARY EMBOLISM</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1108"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>PULMONARY FIBROSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1108"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>PULMONARY HYPERTENSION</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>PULMONARY MASS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>PULMONARY OEDEMA</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="1108"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>PULMONARY TOXICITY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>PULMONARY VEIN STENOSIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>RESPIRATORY DEPRESSION</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1108"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>RESPIRATORY DISTRESS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1108"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>RESPIRATORY FAILURE</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="1108"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>SLEEP APNOEA SYNDROME</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1108"/>
                <counts group_id="E2" events="6" subjects_affected="3" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>WHEEZING</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1096"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ANGIOEDEMA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>DIABETIC FOOT</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="1108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>ERYTHEMA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1096"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>CYTOREDUCTIVE SURGERY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>HERNIA REPAIR</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>HIP ARTHROPLASTY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>IMPLANTABLE DEFIBRILLATOR REMOVAL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>IMPLANTABLE DEFIBRILLATOR REPLACEMENT</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1096"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>AORTIC ANEURYSM</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>AORTIC ANEURYSM RUPTURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>AORTIC DILATATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>AORTIC OCCLUSION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>AORTIC STENOSIS</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>ARTERIOSCLEROSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>ARTERIOVENOUS FISTULA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>DEEP VEIN THROMBOSIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>EMBOLISM</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1108"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>GRANULOMATOSIS WITH POLYANGIITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>HAEMATOMA</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="1108"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="1108"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>HYPERTENSION</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="1108"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>HYPERTENSIVE CRISIS</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="1108"/>
                <counts group_id="E2" events="14" subjects_affected="11" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>HYPOTENSION</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="1108"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>INTERMITTENT CLAUDICATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>ISCHAEMIA</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="1108"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>LYMPHATIC FISTULA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>ORTHOSTATIC HYPOTENSION</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>PERIPHERAL ARTERIAL OCCLUSIVE DISEASE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>PERIPHERAL ARTERY ANEURYSM</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>PERIPHERAL ARTERY THROMBOSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>PERIPHERAL EMBOLISM</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>PERIPHERAL VENOUS DISEASE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>VASCULAR STENOSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1096"/>
              </event>
              <event>
                <sub_title>VASCULITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1096"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1108"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1096"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Study has been designed as a multicenter study and the data generated from Institution/PI's evaluation may not be sufficient to draw meaningful conclusions. Thus, Institution/PI shall not individually publish the results of the Study.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Douglas L. Packer</name_or_title>
      <organization>Mayo Clinic</organization>
      <phone>507-255-6263</phone>
      <email>CABANA@mayo.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

